Clinical Trial

A Real-world Study of Ibrutinib and Venetoclax (I+V) First-Line Treatment Given for Fixed-duration of Time in Participants With Chronic Lymphocytic Leukemia

Study acronym: REALITY-RO
Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to see how well Ibrutinib and Venetoclax (I+V) treatment works (effectiveness) for participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) when it is used in routine, everyday medical care.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-05-16; most recent amendment 2026-07-02.
Trial Details
NCT Number NCT07602088
Lead Sponsor Janssen Research & Development, LLC
Conditions Leukemia, Lymphocytic, Chronic, B-Cell
Enrollment 60 participants
Start Date 2026-05-18
Primary Completion 2029-01-30 (estimated)
Study Completion 2029-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-06